HUP0202898A2 - Integrin receptor antagonists - Google Patents
Integrin receptor antagonistsInfo
- Publication number
- HUP0202898A2 HUP0202898A2 HU0202898A HUP0202898A HUP0202898A2 HU P0202898 A2 HUP0202898 A2 HU P0202898A2 HU 0202898 A HU0202898 A HU 0202898A HU P0202898 A HUP0202898 A HU P0202898A HU P0202898 A2 HUP0202898 A2 HU P0202898A2
- Authority
- HU
- Hungary
- Prior art keywords
- new compounds
- integrin receptor
- subject
- treatment
- heart failure
- Prior art date
Links
- 229940127449 Integrin Receptor Antagonists Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000006495 integrins Human genes 0.000 abstract 3
- 108010044426 integrins Proteins 0.000 abstract 3
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 206010003178 Arterial thrombosis Diseases 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000037147 Hypercalcaemia Diseases 0.000 abstract 1
- 201000002980 Hyperparathyroidism Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 208000024248 Vascular System injury Diseases 0.000 abstract 1
- 208000012339 Vascular injury Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000148 hypercalcaemia Effects 0.000 abstract 1
- 208000030915 hypercalcemia disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 206010062198 microangiopathy Diseases 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000007631 vascular surgery Methods 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Crystallography & Structural Chemistry (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
Abstract
A találmány tárgyát az integrin receptorokhoz kötődő, jellegükettekintve peptid típusú új vegyületek, ezek előállítása, ezekettartalmazó gyógyszerkészítmények, és az ezekből előállítottgyógyszerek különböző betegségek kezelésében való alkalmazása képezi.A találmány szerinti új vegyületek integrin receptor antagonistahatásúak. Ugyancsak a találmány tárgyát képezik azok a kombinációsgyógyszerkészítmények, amelyek az illető integrin receptor antagonistavegyület mellett legalább még egy másik hatóanyagot is tartalmaznak.Az illető új vegyületeket és az ezeket tartalmazógyógyszerkészítményeket például szív-érrendszeri betegségek,érelmeszesedés, érsérülést vagy érműtétet követően kialakuló újbóliérszűkület vagy érelzáródás, veseelégtelenség, mikroangiopathiák,például cukorbetegség következtében fellépő retinopathia vagy reumásízületi gyulladás, artériás trombózis, agyi katasztrófa, rákosbetegségek, csontritkulás, magas vérnyomás, pikkelysömör,mellékpajzsmirigy-túlműködés, Paget-kór, rosszindulatú hypercalcaemia,áttétes csontfelszívódásos sérülések, gyulladások, szívelégtelenség,pangással járó szívelégtelenség, továbbá vírusfertőzések, élősködőkáltal okozott betegségek és bakteriális fertőzések kezelésében és/vagymegelőzésében lehet alkalmazni. ÓThe subject of the invention is peptide-type new compounds that bind to integrin receptors, their production, pharmaceutical preparations containing them, and the use of the drugs produced from them in the treatment of various diseases. The new compounds according to the invention have an integrin receptor antagonistic effect. The subject of the invention is also the combination pharmaceutical preparations which, in addition to the respective integrin receptor antagonist compound, contain at least one other active ingredient. The respective new compounds and the medicinal preparations containing them are, for example, cardiovascular diseases, arteriosclerosis, re-atheroconstriction or vessel occlusion occurring after vascular injury or vascular surgery, kidney failure , microangiopathies, such as retinopathy or rheumatoid arthritis caused by diabetes, arterial thrombosis, cerebral catastrophe, cancers, osteoporosis, high blood pressure, psoriasis, hyperparathyroidism, Paget's disease, malignant hypercalcemia, metastatic bone resorption injuries, inflammation, heart failure, congestive heart failure, it can also be used in the treatment and/or prevention of viral infections, diseases caused by parasites and bacterial infections. HE
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1999119218 DE19919218A1 (en) | 1999-04-28 | 1999-04-28 | New peptide compounds, e.g. aza-heterocyclic substituted beta-alanine derivatives, are integrin receptor antagonists useful e.g. for treating atherosclerosis, cancer, osteoporosis, hypertension or inflammation |
| DE1999148269 DE19948269A1 (en) | 1999-10-06 | 1999-10-06 | New compounds as integrin antagonists useful for treating e.g. cardiovascular disorders, rheumatoid arthritis, kidney failure, stroke, cancer, osteoporosis, psoriasis or infection |
| PCT/EP2000/003469 WO2000066618A1 (en) | 1999-04-28 | 2000-04-17 | Integrin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0202898A2 true HUP0202898A2 (en) | 2002-12-28 |
Family
ID=26053109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0202898A HUP0202898A2 (en) | 1999-04-28 | 2000-04-17 | Integrin receptor antagonists |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1173468A1 (en) |
| JP (1) | JP2003500339A (en) |
| KR (1) | KR20020010618A (en) |
| CN (1) | CN1355811A (en) |
| AU (1) | AU4551500A (en) |
| BG (1) | BG106040A (en) |
| BR (1) | BR0010092A (en) |
| CA (1) | CA2371604A1 (en) |
| CZ (1) | CZ20013846A3 (en) |
| HK (1) | HK1046692A1 (en) |
| HU (1) | HUP0202898A2 (en) |
| IL (1) | IL146146A0 (en) |
| MX (1) | MXPA01010834A (en) |
| NO (1) | NO20015237L (en) |
| PL (1) | PL352777A1 (en) |
| RU (1) | RU2001132141A (en) |
| SK (1) | SK15342001A3 (en) |
| TR (1) | TR200103090T2 (en) |
| WO (1) | WO2000066618A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10204789A1 (en) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Inhibitors of the integrin alpha¶v¶beta6 |
| KR100759130B1 (en) * | 2005-02-12 | 2007-09-19 | 휴메드 주식회사 | Stent Coated with Anti-integrin Antibody and Process for Preparing the Same |
| US8716320B2 (en) * | 2006-07-21 | 2014-05-06 | Replidyne, Inc. | Antibacteriall heterocyclic ureas |
| WO2009015208A1 (en) | 2007-07-23 | 2009-01-29 | Replidyne, Inc. | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds |
| US8293919B2 (en) | 2007-07-23 | 2012-10-23 | Crestone, Inc. | Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds |
| CA2764296A1 (en) * | 2009-06-02 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Derivatives of 6,7-dihydro-5h-imidazo[1,2-.alpha.]imidazole-3-carboxylic acid amides |
| KR20150009952A (en) * | 2012-01-27 | 2015-01-27 | 에프. 호프만-라 로슈 아게 | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3 |
| RU2731807C1 (en) * | 2020-05-05 | 2020-09-08 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт ревматологии имени В.А.Насоновой» (ФГБНУ НИИР им. В.А. Насоновой) | Method for determining indications to beginning of reception of genetic engineering biological preparations with ineffectiveness of basic anti-inflammatory preparations in early forms of psoriatic arthritis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6028223A (en) * | 1995-08-30 | 2000-02-22 | G. D. Searle & Co. | Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid compounds and derivatives thereof |
| GB2327609A (en) * | 1997-07-23 | 1999-02-03 | Merck & Co Inc | A method for eliciting an avß5 or dual avß3/avß5 antagonizing effect |
| SI0928790T1 (en) * | 1998-01-02 | 2003-06-30 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
| BR9910119A (en) * | 1998-04-10 | 2001-10-09 | Searle & Co | Heterocyclic derivatives of glycyl beta-alanine as vitronectin antagonists |
-
2000
- 2000-04-17 PL PL00352777A patent/PL352777A1/en not_active Application Discontinuation
- 2000-04-17 RU RU2001132141/04A patent/RU2001132141A/en unknown
- 2000-04-17 SK SK1534-2001A patent/SK15342001A3/en unknown
- 2000-04-17 KR KR1020017013790A patent/KR20020010618A/en not_active Application Discontinuation
- 2000-04-17 AU AU45515/00A patent/AU4551500A/en not_active Abandoned
- 2000-04-17 CZ CZ20013846A patent/CZ20013846A3/en unknown
- 2000-04-17 HU HU0202898A patent/HUP0202898A2/en unknown
- 2000-04-17 JP JP2000615647A patent/JP2003500339A/en active Pending
- 2000-04-17 CA CA002371604A patent/CA2371604A1/en not_active Abandoned
- 2000-04-17 CN CN00808907A patent/CN1355811A/en active Pending
- 2000-04-17 IL IL14614600A patent/IL146146A0/en unknown
- 2000-04-17 BR BR0010092-7A patent/BR0010092A/en not_active IP Right Cessation
- 2000-04-17 TR TR2001/03090T patent/TR200103090T2/en unknown
- 2000-04-17 MX MXPA01010834A patent/MXPA01010834A/en unknown
- 2000-04-17 WO PCT/EP2000/003469 patent/WO2000066618A1/en not_active Application Discontinuation
- 2000-04-17 EP EP00926971A patent/EP1173468A1/en not_active Withdrawn
-
2001
- 2001-10-23 BG BG106040A patent/BG106040A/en unknown
- 2001-10-26 NO NO20015237A patent/NO20015237L/en not_active Application Discontinuation
-
2002
- 2002-10-30 HK HK02107883.3A patent/HK1046692A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL352777A1 (en) | 2003-09-08 |
| NO20015237L (en) | 2001-12-21 |
| BR0010092A (en) | 2002-06-11 |
| CA2371604A1 (en) | 2000-11-09 |
| EP1173468A1 (en) | 2002-01-23 |
| SK15342001A3 (en) | 2002-06-04 |
| CN1355811A (en) | 2002-06-26 |
| KR20020010618A (en) | 2002-02-04 |
| RU2001132141A (en) | 2004-03-20 |
| HK1046692A1 (en) | 2003-01-24 |
| IL146146A0 (en) | 2002-07-25 |
| NO20015237D0 (en) | 2001-10-26 |
| JP2003500339A (en) | 2003-01-07 |
| MXPA01010834A (en) | 2002-04-24 |
| WO2000066618A1 (en) | 2000-11-09 |
| TR200103090T2 (en) | 2002-05-21 |
| BG106040A (en) | 2002-05-31 |
| AU4551500A (en) | 2000-11-17 |
| CZ20013846A3 (en) | 2002-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Executive Steering Committee on Behalf of the SPORTIF III Investigators | Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial | |
| HUP9802339A2 (en) | Pharmaceutical formulations containing darifenacin | |
| CY1108105T1 (en) | IVANDRONIC ACID FOR THERAPEUTIC TREATMENT AND PREVENTION OF OSTEOPOROSIS | |
| Pantazopoulos et al. | Idiopathic transient osteoporosis of the hip | |
| AR020001A1 (en) | ACTIVATING COMPOUNDS OF hPPARGAMMA AND hPPARALFA, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD FOR THE TREATMENT AND / OR PREVENTION OF A DISEASE MEDIATED BY THE SAME, AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
| UA83182C2 (en) | Compounds effecting glucokinase | |
| AP1818A (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
| DE50008336D1 (en) | MULTILAYER TABLET FOR THE ADMINISTRATION OF A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC | |
| JP2004508410A5 (en) | ||
| HUP0302131A2 (en) | Pharmaceutical tramadol salts, pharmaceutical compositions containing them | |
| DK1392254T3 (en) | Micelle drug delivery system for hydrophobic drugs | |
| AR003121A1 (en) | ADHESION RECEPTOR ANTAGONISTS, PROCEDURE TO PREPARE THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE TO PREPARE MEDICINES AND FIGHT DISEASES | |
| IS7006A (en) | Dihydrogen 3-piperidinopropiophenone and medicinal products containing said compounds | |
| HUP0202898A2 (en) | Integrin receptor antagonists | |
| HUP0100520A1 (en) | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | |
| BG105185A (en) | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases | |
| HUP9802066A2 (en) | Use of alendronate for preparing medicament usefull for lessening the risk of non-vertebral bone fractures | |
| DK1643999T3 (en) | Pyridoxamine for use in the treatment of diabetic nephropathy in type 2 diabetes | |
| TR200101163T2 (en) | Bile water substituted phenyl-alkenoylguanidines, production methods, uses | |
| Gerstein et al. | Left ventricle thrombus after tranexamic acid for spine surgery in an HIV-positive patient | |
| DE50005082D1 (en) | Process for the production of powdery solubilizing aids for solid pharmaceutical dosage forms | |
| De Smet et al. | Tibiocalcaneal Marchetti-Vicenzi nailing in revision arthrodesis for posttraumatic pseudarthrosis of the ankle | |
| JP2021503483A5 (en) | ||
| ATE429826T1 (en) | COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF ALTERED BONE METABOLISM | |
| TNSN05091A1 (en) | Medicament/dosimeter combination packaging |